Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -6164.17% is 363% below its 5-year average of -1332.76%, around the middle of its 5-year range (-13993.73%–442.48%).
9.96% above its 12-month average of -6846.29%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2021 (2021-09-30): -13993.73%.
EBITDA MARGIN
-6164.17%
EBITDA MARGIN AVG TTM
-6846.29%
EBITDA MARGIN AVG 3Y
-1552.78%
EBITDA MARGIN AVG 5Y
-1332.76%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+9.96%
CURRENT VS 3Y AVG
-296.98%
CURRENT VS 5Y AVG
-362.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Corbus Pharmaceuticals Holdings, Inc.
Market Cap
$108.39M
EBITDA Margin
-6164.17%
TTM Avg
-6846.29%
3Y Avg
-1552.78%
5Y Avg
-1332.76%
Market Cap
$109.93M
EBITDA Margin
-624817.90%
TTM Avg
-624817.90%
3Y Avg
-624817.90%
5Y Avg
-624817.90%
Market Cap
$106.23M
EBITDA Margin
5.60%
TTM Avg
2.28%
3Y Avg
0.00%
5Y Avg
-2.15%
Market Cap
$110.75M
EBITDA Margin
-10.96%
TTM Avg
-24.45%
3Y Avg
-32.87%
5Y Avg
-38.11%
Market Cap
$111.17M
EBITDA Margin
28.85%
TTM Avg
28.85%
3Y Avg
28.85%
5Y Avg
28.85%
Market Cap
$112.56M
EBITDA Margin
-475.96%
TTM Avg
-475.96%
3Y Avg
-272.89%
5Y Avg
-272.89%
Market Cap
$104.07M
EBITDA Margin
6.31%
TTM Avg
-127.53%
3Y Avg
-89.97%
5Y Avg
-50.55%
Market Cap
$113.77M
EBITDA Margin
-254.71%
TTM Avg
-369.64%
3Y Avg
-290.17%
5Y Avg
-290.17%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | $108.39M | -6164.17% | -6846.29% | -1552.78% | -1332.76% |
| Immunic, Inc. (IMUX)vs › | $109.93M | -624817.90% | -624817.90% | -624817.90% | -624817.90% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | 5.60% | 2.28% | 0.00% | -2.15% |
| Apyx Medical Corporation (APYX)vs › | $110.75M | -10.96% | -24.45% | -32.87% | -38.11% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 28.85% | 28.85% | 28.85% | 28.85% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $112.56M | -475.96% | -475.96% | -272.89% | -272.89% |
| Definitive Healthcare Corp. (DH)vs › | $104.07M | 6.31% | -127.53% | -89.97% | -50.55% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -254.71% | -369.64% | -290.17% | -290.17% |
| The Joint Corp. (JYNT)vs › | $102.43M | 1.47% | 3.45% | 8.31% | 9.97% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.55M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-6164.2%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2021-09-30 | -13993.73% |
| 2021-06-30 | -12036.94% |
| 2021-03-31 | -2337.36% |
| 2020-12-31 | -3119.13% |
| 2020-09-30 | -2744.29% |
| 2020-06-30 | -13158.11% |
| 2020-03-31 | -1677.91% |
| 2019-12-31 | -1045.92% |
| 2019-09-30 | -958.12% |
| 2019-06-30 | 6.89% |
| 2019-03-31 | -1393.71% |
| 2018-12-31 | -904.67% |
| 2018-09-30 | -1353.56% |
| 2018-06-30 | -1437.29% |
| 2018-03-31 | -1239.74% |
| 2017-12-31 | 442.48% |
| 2017-09-30 | -857.72% |
| 2017-06-30 | -2072.78% |
| 2017-03-31 | -573.63% |
| 2016-12-31 | -2007.74% |
| 2016-09-30 | -715.54% |
| 2016-06-30 | -1051.87% |
| 2016-03-31 | -723.64% |
| 2015-12-31 | -681.62% |
| 2015-09-30 | -1314.27% |
| 2015-06-30 | -2249.75% |
